Interferon alfa-2b is a Recombinant Protein owned by Merck & Co, and is involved in 17 clinical trials, which were completed.

Interferon alpha binds to type I interferon receptors (IFNAR1 and IFNAR2c) which upon dimerization activate two Jak (Janus kinase) tyrosine kinases (Jak1 and Tyk2). These transphosphorylate themselves and phosphorylate the receptors. The phosphorylated INFAR receptors then bind to Stat1 and Stat2 (signal transducers and activators of transcription)which dimerize and activate multiple (~100) immunomodulatory and antiviral proteins. Interferon alpha binds less stably to type I interferon receptors than interferon beta.

The revenue for Interferon alfa-2b is expected to reach a total of $90m through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Interferon alfa-2b NPV Report.

Interferon alfa-2b is currently owned by Merck & Co.

Interferon alfa-2b Overview

Interferon alpha 2b (Intron A, IntronA, Viraferon), an artificial protein which helps to fight off disease in human body. It is formulated as injectable solution and injcetbale lyophilized powder for solution and can be administered intramuscularly, subcutaneously, intralesionaly or intravenously. It is indicated for the treatment of varied type of diseases such as hairy cell leukemia, malignant melanoma, follicular lymphoma, condylomata acuminata, AIDS-related kaposi's sarcoma, chronic hepatitis C, and chronic hepatitis B. The drug is the only FDA-approved treatment to improve survival in people for high-risk malignant melanoma who have already had surgery.

Merck & Co Overview

Merck & Co (Merck) is a biopharmaceutical company focused on the discovery, development, manufacturing and marketing of prescription medicines, biologic therapies, vaccines and animal health products. It offers prescription products for therapy areas related to cardiovascular, cancer, immune disorders, infectious, respiratory and women’s diseases, and diabetes. The company provides animal health products such as vaccines, poultry products, livestock products and aquaculture products. Merck sells medicines to drug wholesalers, retailers, hospitals, government agencies and managed health care providers; and animal health products to veterinarians, distributors and animal producers. The company and its subsidiaries operate in the Americas, Europe, the Middle East, Africa, Asia Pacific, and Latin America. Merck is known as MSD outside the US and Canada and is headquartered in Kenilworth, New Jersey, the US.

The company reported revenues of (US Dollars) US$48,704 million for the fiscal year ended December 2021 (FY2021), an increase of 17.3% over FY2020. In FY2021, the company’s operating margin was 25.7%, compared to an operating margin of 12% in FY2020. In FY2021, the company recorded a net margin of 26.8%, compared to a net margin of 17% in FY2020. The company reported revenues of US$14,959 million for the third quarter ended September 2022, an increase of 2.5% over the previous quarter.

Quick View – Interferon alfa-2b

Report Segments
  • Innovator (NME)
Drug Name
  • Interferon alfa-2b
Administration Pathway
  • Intralesional
  • Intramuscular
  • Intravenous
  • Subcutaneous
Therapeutic Areas
  • Infectious Disease
  • Oncology
Key Companies
  • Sponsor Company: Merck & Co
Highest Development Stage
  • Marketed

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.